1.888.443.3311
    

  Search
 

 

KRAS Mutation Testing

  • An estimated 108,070 cases of colon and 40,740 cases of rectal cancer are expected to occur in 2008.
  • Colorectal cancer is the third most common cancer and second most common cause of cancer-related deaths.
  • An estimated 49,960 deaths from colon and rectal cancers are expected to occur in 2008, accounting for nine percent of all cancer deaths.

Monoclonal antibodies approved to treat mCRC

  • Avastin® (bevacizumab) blocks the growth of blood vessels to the tumor.
  • Erbitux® (cetuximab) and Vectibix® (panitumumab) block the effect of hormone-like factors that promote cancer cell growth.

Print